Senior-led FDA regulatory consulting for biotech startups developing biologics, cell and gene therapies, and combination products with complex paths to the clinic.
Chosen for nearly two dozen FDA data-integrity audits.
Clinical discipline shaped by decades of FDA scrutiny.
Guiding high‑stakes medtech and biotech programs from early strategy to market.
Biotech startups face critical FDA decisions long before the first patient is enrolled. Many are also caught in the middle, running programs that look more like drug development than device work on budgets that aren’t built for pharma-scale CROs and vendors.
Health Policy Associates (HPA) has provided regulatory and clinical guidance to biologic, cellular, and gene therapy companies for more than two decades, including managing five concurrent Phase 2 studies for a prominent stem cell therapy program. Our biotech consulting gives lean teams senior clinical and regulatory expertise without enterprise overhead.
We provide you with a concrete regulatory plan: clear documents and working sessions that turn uncertainty into a development path you can defend to your board and investors.
Most engagements begin at a moment when the next FDA decision will shape the program’s cost, timeline, and credibility with investors.
Your first formal interaction with the FDA sets the tone for the rest of the program. Sponsors who arrive with broad, unfocused questions often leave with feedback that is too general to act on.
We help guide your preparation for a pre-IND meeting, or an INTERACT meeting with the FDA’s Center for Biologics Evaluation and Research (CBER), and then translate the agency’s feedback into clear, prioritized next steps. When a program needs specialized IND expertise, we bring in experienced outside specialists and coordinate the work alongside our own team.
Many biotech products don’t fit neatly into one regulatory category. How the FDA classifies your product determines which center leads the review, what evidence you’ll need, and how long and costly the path to market will be.
We assess how the agency is likely to classify your product and build a defensible rationale before you commit to a direction — including for combination products that sit at the boundary of two regulatory frameworks.
A product with biologic components may even qualify as a device when its primary function is physical, which can significantly reduce development time and cost.
Investors increasingly evaluate the regulatory path as closely as the science, and an unclear pathway or optimistic timeline can raise difficult questions.
We build a regulatory plan that details the pathway, evidence requirements, key FDA milestones, and the risks most likely to affect your schedule and funding. We then summarize it in clear business language your leadership can confidently present to the board and investors.
As preclinical work nears completion, many startups need a partner for their first clinical trial, which is often where budgets come under pressure.
We develop a protocol that is feasible, enrollable, and aligned with FDA expectations. Because we handle regulatory, clinical, and quality work under one roof, your FDA commitments and trial operations stay aligned from the start. We can also support later-stage trials as your product advances.
A clinical hold or critical FDA feedback can stop a program in its tracks — and put the next funding milestone at risk. We help you identify what the FDA actually needs, trace the root causes, and build a response designed to restore momentum.
Our own clinical program has been through a six-day direct FDA inspection with zero observations, so we know what the agency looks for when it takes a close look.
We translate FDA expectations for biologics and novel therapies into a clear development plan, so your lean team knows what to do now and what can wait.
We help you make classification, preclinical, and clinical decisions that hold up when the FDA, your board, and investors start asking hard questions.
The same senior consultants stay with your program from first FDA interaction into the clinic, with disciplined scoping that keeps costs under control.
The scope of a biotech engagement depends on your product type, where you are in development, and what the FDA has already said. Typical engagements include some or all of the following:
A regulatory pathway opinion outlining how the FDA is likely to classify your product, which submissions and meetings lie ahead, and the timing and resource implications for your development plan.
A review of your current preclinical, manufacturing, and clinical evidence against FDA expectations, identifying what is missing or misaligned.
A prioritized roadmap that sequences the required testing, documentation, and FDA interactions, so your team knows what to do, in what order, and why.
Coordination of key regulatory submissions, such as pre-IND briefing packages and IND sections, with experienced outside specialists brought in to lead the drafting where your program needs it.
Concise materials that explain the recommended path, key risks, and next steps for leadership, boards, and investors.
These deliverables follow the same approach behind our Regulatory Consulting Services, adapted to the realities of an early-stage biotech company.
Some biotech programs need support beyond regulatory strategy. When the work demands it, we can extend the engagement to include:
when your program moves into clinical studies and you need protocol development, site management, monitoring, and data analysis under one roof.
when your product pairs a biologic or drug with a device and lead-center determination or cross-center coordination must be resolved.
when manufacturing processes, suppliers, or quality systems need to be ready for FDA scrutiny before your program scales.
when your study needs database design, real-time data access, and customized analysis that will hold up in a regulatory submission.
We scope these extensions based on your program’s specific needs and can connect the work directly to our Clinical Trial Strategy & Execution, Combination Product Consulting, Quality Systems / Compliance Consulting, US FDA GMP Auditing, and Data Management and Analysis services.
When your program is ready to begin clinical studies, we can extend the engagement into Clinical Trial Strategy & Execution, so your regulatory commitments and trial operations stay aligned.
For a biotech startup, the regulatory decisions made before the first clinical trial shape everything that follows, from how the FDA reviews your product to how investors value your company.
HPA works alongside your leadership so you can choose a defensible path, close the gaps that matter, and move into clinical development with a plan your team, board, and investors can stand behind.